Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Open-label Selinexor Study in Relapsed/Refractory DLBCL
2014-001977-15Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Objective disease response. Started Oct 2014; status: completed.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-001977-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001977-15.